![Elena Ridloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Elena Ridloff
Directeur Financier/CFO chez
SIONNA THERAPEUTICS, INC.
Fortune : 2 M $ au 31/07/2026
Profil
Mme Elena H. Ridloff, CFA, est directrice indépendante de Kymera Therapeutics, Inc. et de Kronos Bio, Inc. et directrice financière et vice-présidente exécutive d'ACADIA Pharmaceuticals, Inc. Elle siège au conseil d'administration de Kymera Therapeutics, Inc. et de Kronos Bio, Inc. Auparavant, Mme Ridloff a occupé les postes de vice-présidente des relations avec les investisseurs chez Alexion Pharmaceuticals, Inc, de directrice générale et membre de la direction chez BioVision, Inc, d'analyste principale chez Maverick Capital Ltd et d'analyste principale chez Paramount BioCapital Asset Management, Inc. Elle a obtenu son diplôme de premier cycle à l'Université de Pennsylvanie.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/04/2026 | 38 532 ( 0,09 % ) | 2 M $ | 31/07/2026 | |
IMMUNIC, INC. -.--% | 06/08/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
Postes actifs de Elena Ridloff
| Sociétés | Poste | Début |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/03/2021 |
| SIONNA THERAPEUTICS, INC. | Directeur Financier/CFO | 01/01/2021 |
| IMMUNIC, INC. | Directeur/Membre du Conseil | 06/08/2026 |
Anciens postes connus de Elena Ridloff
| Sociétés | Poste | Fin |
|---|---|---|
| KRONOS BIO, INC. | Directeur/Membre du Conseil | 20/06/2025 |
| ACADIA PHARMACEUTICALS INC. | Directeur Financier/CFO | 10/09/2021 |
| ALEXION PHARMACEUTICALS, INC. | Investor Relations Contact | 01/03/2018 |
BioVision, Inc.
 BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Directeur Général | 01/04/2014 |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Analyst-Equity | 01/01/2012 |
Formation de Elena Ridloff
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
78
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Paramount BioCapital Asset Management manages hedge funds and private equity funds that focus on investments in healthcare and life sciences companies. The firm invests globally, with emphasis on the stocks of small-cap healthcare technology companies. | Finance |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that they believe offer the highest returns relative to risk, regardless of index weightings, market capitalization, or style orientations. Their research is augmented by a top-down view of individual industries and the efforts of their quantitative research team. The firm’s investment team is organized into four industry sector teams: consumer, healthcare, cyclicals, and technology. The industry sector teams are supported by two disciplined research teams (private investments and quantitative).; | Finance |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
BioVision, Inc.
BioVision, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kymera Therapeutics, Inc.
 Kymera Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops immunology medicines for health problems | Health Technology |
Kronos Bio, Inc.
 Kronos Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | Health Technology |
Stealth BioTherapeutics, Inc.
 Stealth BioTherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat the mitochondrial dysfunctions and age-related diseases | Health Technology |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for CF and rare diseases | Health Technology |
